Dermatology

Isotretinoin exerts dose-dependent inhibition of sebaceous gland function, thereby reducing sebum secretion, which is associated with improvement in nodular acne.

Tecnu Rash Relief Spray treats skin irritation caused by sunburn, minor skin irritations, insect bites, and other minor skin issues.

The topical therapy demonstrated significant improvements in the study, based on IGA success and other endpoints, according to investigators.

Clinically meaningful results may be a huge step forward in the development of a new therapy for systemic lupus erythematosus.

Better Nail is an anti-fungal product for fungus under and around the nails.

Baricitinib (Olumiant; Eli Lilly and Company) is the first systemic treatment to be approved by the FDA for severe alopecia areata, which affects an estimated 300,000 patients in the United States.

Approval in this patient population makes dupilumab the first and only biologic medicine approved for the treatment of moderate-to-severe atopic dermatitis from infancy through adulthood.

Further analyses showed guselkumab provided patients with sustained improvements in measures of health-related quality of life, fatigue, pain, and work productivity.

Dupilumab is under clinical development, and the efficacy and safety have not been fully evaluated by any regulatory authorities.

Study findings provide evidence that preventative antibiotics improve health outcomes for babies and mothers, investigator say.

The FDA has approved abrocitinib tablets to treat adults with moderate-to-severe, refractory atopic dermatitis.

Long-term extension trial results show a consistent safety profile and durable efficacy for the treatment of adults with the skin condition.

Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.

With Epsolay treatment, inflammatory lesions of rosacea were reduced by nearly 70% by the end of both 12-week trials compared with a 38% to 46% reduction with the vehicle cream.

Ruxolitinib (Opzelura) is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis.

On this week's episode, Suzy is joined by Michelle Henry, MD, from Skin & Aesthetic Surgery of Manhattan, a board-certified dermatologist located in New York.

Among individuals taking the medication with standard-of-care topical corticosteroids, approximately 41% achieved clear or almost clear skin at 16 weeks.

The phase 3, multicenter, randomized, double-blinded, comparative clinical study was evaluating the efficacy and safety of ABP 654 compared with ustekinumab in adult patients with moderate to severe plaque psoriasis.

Abrocitinib (Cibinqo) is a Janus kinase inhibitor indicated for the treatment of adults with refractory moderate-to-severe atopic dermatitis.

Aftersun Aloe Vera naturally soothes sunburns, minor skin irritations, and abrasions.

Regeneron’s supplemental biologics license application for the drug targets patients aged 12 years and older.

Ruxolitinib (Opzelura; Incyte) is a Janus kinase inhibitor indicated for patients 12 years of age or older whose atopic dermatitis is inadequately controlled with topical prescription therapies or when those therapies are inappropriate.

Lidocaine is a local anesthetic that offers temporary relief of pain and itching.

Sirolimus is the first topical treatment to gain FDA approval for facial angiofibroma associated with tuberous sclerosis complex.

Calamine spray treats insect bites, rashes, minor skin irritations, and minor cuts.